Japan, U.S. Discuss $19 Billion GlobalFoundries Chip Plant 
Fed Rate Hike Threatens Housing as U.S. Growth Leans on AI, Citi Says 
Gold Prices Rise as Oil Slump Eases Fed Rate Hike Fears 
NASA, Boeing Discuss Expanding Starliner Missions 
Wall Street Mixed as Treasury Yields Rise After Fed Hike 
CNN, MS NOW and Politico Sue Trump Over White House Media Ban 
France Debt-to-GDP Ratio Seen Hitting Record 119.3% in 2026 
Oil Prices Rise as U.S.-Iran Talks Fuel Diplomacy Hopes 
Prysmian, Rio Tinto Supply Low-Carbon Cables for Amazon Ohio Data Center 
Bessent, He Lifeng to Discuss AI Security and Trade in New York 
White House Bars CNN, MS NOW and Politico Reporters 
South Korea to Brief Lawmakers on $350 Billion US Investment Package 
Wall Street Surges as Meta Leads AI Rally, Oil Prices Fall 
LVMH-Hermès Dispute Deepens Over Secret 2002 Share Deal 
Strait of Hormuz Oil Shipments Hit Six-Month High as U.S. Clears Mines 
OpenAI Urges US-Led Global Standards for Frontier AI 
Add as a preferred source on Google
Samsung Biologics is said to be most likely to sign a deal with Moderna, an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts. The contract is for the production of COVID-19 vaccine in South Korea.
Samsung and Moderna’s anticipated announcement
As per The Korea Herald, Samsung Biologics and Moderna may work together to boost vaccine production amid the vaccine shortage in the country. It was reported that the two companies may formally announce their deal at the summit where S. Korea’s President Moon Jae In and US President Joe Biden are set to meet.
A local TV station was said to have reported about the possibility of this business negotiation last weekend. Other media outlets followed suit and shared related reports.
In any case, Samsung Biologics did not confirm if it will indeed sign a contract with Moderna for vaccine production and supply. It was quite vague as the Incheon-based biotechnology company did not deny the reports as well. In a regulatory filing, there was a statement saying there is no decision yet about Moderna’s COVID-19 being manufactured in S. Korea.
The guessing game
There have been lots of reports as to which company that Moderna will partner with as it is reported to be very interested in producing its vaccine in the said Asian region. Various firms were mentioned, and initial rumor is that it will work with Hanmi Pharmaceuticals or GC Pharma.
And now, the most promising candidate for a deal with Moderna is reportedly Samsung Biologics that was suddenly added to the list of potential partners. Moderna’s CEO, Stephane Bancel, may visit S. Korea this month to survey as per the reports.
Maeil Business News pointed out that it was also reported earlier that Samsung Biologics will produce Pfizer vaccine but this was vehemently denied but with Moderna, it was different as the Korean firm would not acknowledge or deny and only saying that “nothing has been finalized yet.”
Thus, it was speculated that Samsung Biologics and Moderna are more likely to confirm their contract soon. The rumors of the partnership were heightened by the fact that the American pharma already started looking for senior executives for its office that will soon open in Korea.
